Progyny vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Progyny is a fertility and family building benefits management company providing employer-sponsored fertility coverage that improves outcomes and reduces total fertility spend.
About
Progyny is a publicly traded fertility benefits management company founded in 2008 that has become the leading provider of employer-sponsored fertility benefits in the United States. The company manages fertility coverage for self-insured employers, providing access to a national network of top-tier fertility clinics, a proprietary Smart Cycle benefits design that bundles all medically necessary components of a treatment cycle, and dedicated patient care advocates who guide employees through fertility treatment. Progyny went public on Nasdaq in 2019 under the ticker PGNY and serves over 430 employers covering over 6 million lives including many Fortune 500 companies. The company has published clinical outcomes data demonstrating higher live birth rates, lower multiple birth rates, and lower NICU costs compared to traditional indemnity fertility coverage, translating into healthcare cost savings that offset the benefit cost for employers. Progyny's Smart Cycle design bundles medications, lab tests, and procedures into a single benefit unit that eliminates the piecemeal authorization challenges of traditional insurance coverage. The company competes with Carrot Fertility and Kindbody in the employer fertility benefits market.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.